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Background: Hearing loss is caused by several environmental and genetic factors and the proportion attributed to
inherited causes is assumed at 50 ~ 60% . Mutations in GJB2 and mitochondrial DNA (mtDNA) 12S rRNA are the
most common molecular etiology for nonsyndromic sensorineural hearing loss (NSHL). The mutation spectra of
these genes vary among different ethnic groups.
Methods: To add the molecular etiologic information of hearing loss in the Chinese population, a total of 658
unrelated patients with NSHL from Jiangsu Province of China were selected for mutational screening including
GJB2 and mtDNA 12S rRNA genes using PCR and DNA sequencing technology. As for controls, 462 normal-hearing
individuals were collected.
Results: A total of 9 pathogenic mutations in the GJB2 and 7 pathogenic mutations in the 12S rRNA gene were
identified. Of all patients, 70 had monoallelic GJB2 coding region mutation in the heterozygous state, 94 carried two
confirmed pathogenic mutations including 79 homozygotes and 15 compound heterozygotes. The 235delC appears to
be the most common deafness-causing GJB2 mutation (102/658, 15.50% ). No mutations or variants in the GJB2 exon1
and basal promoter region were found. In these patients, 4 subjects carried the m.1494C > T mutation (0.61% ) and 39
subjects harbored the m.1555A > G mutation (5.93% ) in mtDNA 12S rRNA gene. A novel sequence variant at m.1222A >
G in the 12S rRNA gene was identified, which could alter the secondary structure of the 12S rRNA.
Conclusion: The mutation spectrum and prevalence of GJB2 and mtDNA 12S rRNA genes in Jiangsu population are
similar to other areas of China. There are in total 31.46% of the patients with NSHL carry deafness-causing mutation in
GJB2 or mtDNA 12S rRNA genes. Mutation in GJB2 gene is the most common factor, mtDNA 12S rRNA also plays an
important part in the pathogenesis of hearing loss in Jiangsu Province areas. The m.1222A > G was found to be a new
candidate mutation associated with hearing loss. Our results indicated the necessity of genetic screening for mutations of
these genes in Jiangsu patients with NSHL.
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Hearing loss is caused by several environmental and gen-
etic factors, and the proportion attributed to inherited
causes is assumed at 50-60% [1]. About 70% of which are
nonsyndromic hearing loss (NSHL) since hearing loss is
the only symptom. Genetic hearing loss of nonsyndromic* Correspondence: xing-gq@163.com; caoxin@njmu.edu.cn
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reproduction in any medium, provided the orform can follow a pattern of autosomal dominant (DFNA),
autosomal recessive (DFNB), or X-linked recessive, and
mitochondrial inheritance [2].
To date, there are 134 genetic loci and 80 different
genes that have been described for NSHL in human [3].
It is believed that alterations in several members of the
connexin protein family and mtDNA 12S rRNA contrib-
ute to the development of the majority of genetic hear-
ing losses, in which connexin 26 (GJB2) gene mutations
are particularly an important cause of NSHL and mainly
linked to pattern of autosomal recessive, and the single-. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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identified as a major cause of aminoglycoside-induced
NSHL [4-8].
It is estimated that there are approximately 20 million
babies born every year in China, of whom about 30,000
are expected to have congenital hearing loss [9]. Carrier
frequencies of some mutational hot spots associated with
NSHL from different areas and ethnic backgrounds have
been reported [10-15], but the molecular etiology of
NSHL in the Chinese Jiangsu Province population has not
been investigated systematically. To further extend the
epidemiological data of common gene mutations in Chin-
ese population, we screened the GJB2 and mitochondrial
12S rRNA genes to determine the etiology of hearing loss
in Jiangsu Province.Materials and methods
Subjects and audiological examinations
A total of 658 unrelated hearing loss subjects from 6 typ-
ical cities of Jiangsu Province, China were collected. All
the individuals were recruited to participate in this study
by signing a written informed consent as approved by the
Ethical Committee of Nanjing Medical University for Hu-
man Studies, and to donate a peripheral blood sample.
The protocol was reviewed and genetic studies were
conducted on two groups: a case group with moderate to
profound and NSHL (n = 658) aged 2–45 (11.3 ± 2.6)
years, and a control group (n = 462) with normal hearing
aged 8–34 (11.5 ± 2.9) years. The female–male ratio of
these groups are 344/314 and 235/227, respectively. The
blood samples of 658 cases were obtained from a panel of
sporadic hearing loss individuals collected in the Oto-
logical Clinics between January 2008 and July 2012, and
the 462 control blood samples were gotten from a panel of
unaffected individuals in Jiangsu province. All subjects
were Han Chinese in origin, and were evaluated through
otological examination and audiological evaluations in-
cluding pure-tone audiometry (Madsen Orbiter 922),
immittance (Madsen Zodiac 901), auditory brainstem re-
sponse (ABR) (Interacoustic EP25), and transient evoked
otoacoustic emissions (Madsen Celesta 503). Hearing loss
is defined by the level of hearing loss in the better ear for
pure-tone threshold average in the speech frequencies 0.5,
1, 2, and 4 k HZ. Hearing loss of 26-40 dB was considered
mild; 41-60 dB, moderate; 61-80 dB, severe, and more
than 80 dB, profound.
Mutational analysis of GJB2 and mitochondrial 12S
rRNA genes
The mutations on the GJB2 and mtDNA 12S rRNA genes
were selected for molecular analysis in all 658 NSHL cases
and 462 normal controls. The genomic DNA was isolated
from peripheral blood leukocytes of all participants usingPuregene DNA Isolation Kits (Watson Biotechnologies
Inc, Shanghai China). The quality and quantity of purified
genomic DNA were determined by gel electrophoresis
(0.8% agarose) and spectrophotometry.
The coding exon (exon 2) and flanking intronic regions
of GJB2 gene were amplified by PCR using primers F (5′
TTGGTGTTTGCTCAGGAAGA3′) and R (5′ GGCCTA
CAGGGGTTT CAAAT 3′). The GJB2 exon 1, its flanking
donor splice site and the GJB2 basal promoter were ampli-
fied with the primers F (5′ TGGGGGCACTTGGGGAAC
TCA 3′) and R (5′ GCAGAAACGCCCGCTCCAGAA 3′).
DNA fragments of subjects spanning the mtDNA 12S
rRNA gene were also amplified by PCR with primers: P1 F
(5′ CTCCTCAAAGCAATACACTG 3′) and R (5′ TGCT
AAATCCACCTTCGACC 3′); P2 F (5′ CGATCAACCTC
ACCACCTCT 3′) and R (5′ TGGACAACCAGCTATCA
CCA 3′).
All the PCR products were purified on QIA-quick spin
columns (Qiagen, Valencia, CA) and subjected to direct
sequencing by BigDye Terminator Cycle Sequencing kit
(version v.3.1) and ABI genetic analyzer 3730 (Applied
Biosystems, Foster City, CA, USA) attached Sequencing
Analysis software (version 3.7). The resultant sequence
data of GJB2 gene were compared with the reference se-
quence of wild type GJB2 (GenBank No. NG_008358.1)
and the genotypes of GJB2 gene in all subjects were subse-
quently analyzed. PolyPhen-2 (http://genetics.bwh.har-
vard.edu/pph2/) and SIFT (http://sift.jcvi.org/) were used
to predict the effect of previously reported and novel mis-
sense changes on protein function. The sequencing data
of mtDNA 12S rRNA gene were compared with the
updated consensus Cambridge reference sequence (Gen-
Bank No. AC_000021.2) to identify mtDNA variants. The
uniqueness of each mutation was evaluated by comparison
with the MITOMAP, and the Uppsala mtDB database.Phylogenetic analysis and structural analysis of
mitochondrial 12S rRNA
A total of 22 primates’ mtDNA 12S rRNA sequences
were selected to analyze the interspecific difference by
ClustalW. The additional file lists the mammalian spe-
cies and the accession numbers of the mtDNA 12S
rRNA (Additional file 1: Table S1). The conservation
index (CI) was calculated by comparing the human nu-
cleotide variants with other 21 primates. The CI was
then defined as the amount of species from the list of
22 different primates that have the wild-type nucleotide
at that position.
Pathogenicity of the novel variants was also evaluated
by predicting the secondary structures of human
mtDNA 12S rRNA transcripts with or without the vari-
ant using the RNAdraw program (RNAdraw V1.1,
http://www.rnadraw.com).
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GJB2 gene mutations
As shown in Table 1, there were totally fifteen kinds of dif-
ferent GJB2 variations detected in the patients and controls.
Among these, one variant c.257C >G (T86R) in coding re-
gion was novel pathogenic mutation that was identified in
two deaf siblings compound with c.605ins46 mutation in
the exon 2. The two siblings came from a Chinese Han
family and suffered from prelingual and nonsyndromic
hearing loss. The c.257C >G (T86R) mutation was also pre-
dicted to be damaging by PolyPhen-2 and SIFT. Eight vari-
ants including c.35delG, c.109G >A, c.176del16, c.235delC,
c.299delAT, c.504insGCAA, c.605ins46 and c.608TC >
AA were pathological mutations that has been reported
previously. Four nucleotide changes containing c.79G>A,
c.101 T >C, c.341A >G and c.608 T>C were polymor-
phisms. The category of two nucleotide changes (c.368C >A,
c.571 T >C) was unknown (http://davinci.crg.es/deafness/).
The carrier frequencies of deafness-causing GJB2 muta-
tions in our case group were 0.30% for c.35delG, 2.28% for
c.109G >A, 3.19% for c.176del16, 15.50% for c.235delC,
4.71% for c.299delAT, 0.30% for c.504insGCAA, 0.30% for
c.605ins46 and 0.30% for c.608TC >AA, respectively. Thus,
the total carrier frequency of pathogenic GJB2 mutations
in the case group was 24.92% (164/658). The 235delC
appeared to be the most common deafness-causing GJB2
mutation (102/658, 15.50% ) with the highest allele fre-
quency. While in the control group, only eleven subjects
were detected to carry the heterozygous deafness-causing
mutations.
The detailed genotypes of the patients and controls were
summarized as Table 2. Of all patients, 70 had monoallelic
GJB2 coding region mutations in the heterozygous state,
94 carried two confirmed pathogenic mutations including
79 homozygotes and 15 compound heterozygotes. The
genotypes-phenotypes correlations of GJB2 gene mutations
in 658 patients were shown in Table 3. In the control
group, we detected three c.109G >A, two c.176del16, three
c.235delC and two c.299delAT heterozygotes, representing
2.38% of all normal hearing individuals, which coincided
with previous study in different control cohorts. No muta-
tions or variants in the GJB2 exon1 and basal promoter re-
gion were found in both the case and control groups.
Mitochondrial 12S rRNA gene mutations
The two DNA fragments spanning the entire coding re-
gion of the 12S rRNA gene were amplified by PCR from
genomic DNA of all subjects, and each fragment was
purified and subsequently analyzed by direct DNA se-
quencing. The sequencing results were compared with
the updated Cambridge consensus sequence. As shown
in Table 4, there were totally 30 kinds of nucleotide
changes identified in the 12S rRNA gene. All the nucleo-
tide changes were verified by sequence analysis of bothstrands and appeared to be homoplasmy. Among these,
four subjects with severe or profound hearing loss car-
ried the m.1494C > T mutation. Three of them had a
history of exposure to aminoglycosides before deafness.
Thirty-nine patients harbored the m.1555A > G muta-
tion. These translate to a frequency of 5.93% and 0.61%
for the m.1555A > G and m.1494C > T mutations in
deafness population of Jiangsu Province, respectively.
Meanwhile, 6 subjects harbored the known deafness-
associated m.1095 T > C mutation and 18 subjects car-
ried the putative pathogenic mutations at position of
961 (m.961insC, m. 961delT and m.961 T > C).
A novel sequence variant, m.1222A > G in the 12S
rRNA gene, was identified in one patient with profound
hearing loss. This variant was not found in 462 controls.
Furthermore, we used RNAdraw software to analyze the
secondary structure of 12S rRNA to localize m.1222A >
G variant with either a stem or a loop and to analyze if
the base changes within stems alter. As shown in
Figure 1, the secondary structure of the 12S rRNA
m.1222A > G variant predicted by RNAdraw indicated
that the m.1222A > G induced a marked structural alter-
ation in the transcript.
In addition, phylogenetic analysis was performed by
comparing the human 12S rRNA nucleotide variants with
other 21 primates. As shown in Table 4, conservation index
(CI) among the variants ranged from 13.6% (m.1009C >T
variant) to 100% (m.750A >G, m.752C >T, m.1095 T > C,
m.1222A >G, m.1438A >G and m.1598G >A variants). Of
30 variants, 15 had a CI more than 78% , 8 had a CI be-
tween 78% and 50% , and the remaining had CIs below
50% . In addition to the m.1555A >G and m.1494C >T
mutations, the m.789 T > C and m.1222A >G variants,
which were absent in the 462 controls and whose CIs were
above 78% , were the putative deafness-associated variants.
In contrast, other 9 variants including m.663A >G,
m.681 T >C, m.750A >G, m.752C >T, m.827A >G,
m.1107 T >C, m.1438A >G and m.1598G >A, which were
present in both the case and control groups, appeared to be
the polymorphisms even though they had CIs above 78%.Discussion
Hearing loss is the most common neurosensory disorder
in humans. Approximately half of the cases have a gen-
etic etiology with extraordinary genetic heterogeneity.
For many populations, the most common cause for
NSHL is mutated Connexin 26, a gap junction protein
encoded by the GJB2 gene, which is expressed in the
cochlea and may play a role in K+ circulation between
different partitions in the cochlea. GJB2 gene is com-
posed of 2 exons separated by an intron. Its coding re-
gion is entirely contained in exon 2. The basal promoter
activity resides in the first 128 nucleotides upstream of









Previous report Numbers found in




controls (N = 462)
Freq in
controls (%)
c.35delG Frameshift IC1 Pathogenic N/A N/A Yes 2 0.30 0 0.00
c.79G > A Val27Ile TM1 Polymorphism 1.000 0.15 Yes 135 20.52 65 14.07
c.101 T > C Met34Thr TM1 Polymorphism 0.038 0.12 Yes 3 0.46 1 0.22
c.109G > A Val37Ile TM1 Pathogenic 1.000 0.12 Yes 15 2.28 4 0.87
c.176del16 Frameshift EC1 Pathogenic N/A N/A Yes 21 3.19 2 0.43
c.235delC Frameshift TM2 Pathogenic N/A N/A Yes 102 15.50 3 0.65
c.257C > G Thr86Arg TM2 Pathogenic 1.000 0.00 None 2 0.30 0 0.00
c.299delAT Frameshift IC2 Pathogenic N/A N/A Yes 31 4.71 2 0.43
c.341A > G Glu114Gly IC2 Polymorphism 0.001 0.27 Yes 25 3.80 9 1.95
c.368C > A Thr123Asn IC2 Unknown 0.000 0.53 Yes 5 0.76 1 0.22
c.504insAAGG Frameshift EC2 Pathogenic N/A N/A Yes 2 0.30 0 0.00
c.571 T > C Phe191Leu EC2 Unknown 1.000 0.00 Yes 4 0.61 0 0.00
c.605ins46 Stop at aa 202 TM4 Pathogenic N/A N/A Yes 2 0.30 0 0.00
c.608TC > AA Ile203Lys TM4 Pathogenic N/A 0.00 Yes 2 0.30 0 0.00
c.608 T > C Ile203Thr TM4 Polymorphism 0.906 0.00 Yes 2 0.30 1 0.22
Total 353 53.65 88 19.05
IC intracellular, TM transmembrane, EC extracellular.

















Table 2 Genotypes of GJB2 gene in patients with hearing loss and controls
Allele 1 Allele 2 Numbers found in
patients (N = 658)
Numbers found in
controls (N = 462)
Exon 1 or splice site
nucleotide change
Nucleotide change Consequence or amino
acid change
Category Nucleotide change Consequence or amino
acid change
Category
c.35delG Frameshift mutation pathogenic - - - 1 0 -
c.109G > A Val37Ile pathogenic - - - 7 3 -
c.176del16 Frameshift mutation pathogenic - - - 6 2 -
c.235delC Frameshift mutation pathogenic - - - 40 3 -
c.299delAT Frameshift mutation pathogenic - - - 12 2 -
c.504insAAGG Frameshift pathogenic - - - 2 0 -
c.608TC > AA Ile203Lys pathogenic - - - 2 0 -
c.35delG Frameshift mutation pathogenic c.235delC Frameshift mutation pathogenic 1 0 -
c.109G > A Val37Ile pathogenic c.109G > A Val37Ile pathogenic 8 0 -
c.176del16 Frameshift mutation pathogenic c.176del16 Frameshift mutation pathogenic 7 0 -
c.176del16 Frameshift mutation pathogenic c.235delC Frameshift mutation pathogenic 5 0 -
c.176del16 Frameshift mutation pathogenic c.299delAT Frameshift mutation pathogenic 3 0 -
c.235delC Frameshift mutation pathogenic c.235delC Frameshift mutation pathogenic 52 0 -
c.235delC Frameshift mutation pathogenic c.299delAT Frameshift mutation pathogenic 4 0 -
c.257C > G Thr86Arg pathogenic c.605ins46 Stop at aa 202 pathogenic 2 0 -
c.299delAT Frameshift mutation pathogenic c.299delAT Frameshift mutation pathogenic 12 0 -
c.79G > A Val27Ile polymorphism - - - 64 28 -
c.101 T > C Met34Thr polymorphism - - - 3 1 -
c.79G > A Val27Ile polymorphism c.79G > A Val27Ile polymorphism 49 13 -
c.79G > A Val27Ile polymorphism c.341A > G Glu114Gly polymorphism 9 1 -
c.341A > G Glu114Gly polymorphism c.341A > G Glu114Gly polymorphism 5 1
c.341A > G Glu114Gly polymorphism c.79G > A
c.341A > G Val27Ile
Glu114Gly polymorphism
polymorphism 2 0 -
c.79G > A Val27Ile polymorphism c.368C > A Thr123Asn unknown 11 3 -
c.608 T > C Ile203Thr polymorphism c.608 T > C Ile203Thr polymorphism 4 0 -
c.368C > A Thr123Asn unknown - - - 1 1 -

















Table 3 GJB2 genotypes and phenotypes in the 658 unrelated patients





c.35delG/c.235delC 1 1 Prelingual
c.109G > A/c.109G > A 8 2 2 4 Post (2), pre (6)
c.176del16/c.176del16 7 3 4 Prelingual
c.176del16/c.235delC 5 1 4 Prelingual
c.176del16/c.299delAT 3 3 Prelingual
c.235delC/c.235delC 52 1 11 40 Prelingual
c.235delC/c.299delAT 4 4 Prelingual
c.257C > G/c.605ins46 2 2 Prelingual
c.299delAT/c.299delAT 12 1 1 10 Prelingual
Heterozygous mutations 70
c.35delG 1 1 Prelingual
c.109G > A 7 2 3 2 Post (3), pre (4)
c.176del16 6 1 5 Prelingual
c.235delC 40 3 8 29 Post (8), pre (32)
c.299delAT 12 1 3 8 Prelingual
c.504insAAGG 2 1 1 Prelingual
c.608TC > AA 2 1 1 Prelingual
Polymorphism and unknown 152
c.79G > A 64 13 22 29 Post (3), pre (61)
c.101 T > C 3 1 1 1 Post (1), pre (2)
c.79G > A/c.79G > A 49 11 15 23 Post (5), pre (44)
c.79G > A/c.341A > G 9 1 1 7 Prelingual
c.341A > G/c.341A > G 5 2 2 1 Prelingual
c.341A > G/c.341A > G/c.79G > A 2 1 1 Prelingual
c.79G > A/c.368C > A 11 1 1 9 Prelingual
c.368C > A 1 1 Prelingual
c.571 T > C 4 2 2 Prelingual
c.608 T > C/c.608 T > C 4 1 3 Prelingual
No mutations identified 342 28 52 262
Total 658
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boxes, at position 281 and 293 from the TSP, which is
important for transcription [17]. Previous reports have
suggested that the mutation spectrum and prevalence
of GJB2 vary significantly among different ethnic
groups. GJB2 mutations with the c.35delG, c.167delT,
c.235delC and c.427C > T alleles were responsible for
a large proportion of NSHL in European, American,
African and the Asian [18-25]. In the Chinese popula-
tions, the 235delC is responsible for up to 21% of cases
with NSHL [9].
Similar to other previous reports of China [10,14,26],
our study showed that GJB2 mutations were animportant cause of NSHL in Jiangsu deafness popula-
tions, and the most common GJB2 mutation detected in
our study group was the c.235delC (102/658; 15.50% ).
While the c.35delG mutation, which is prevalent in the
Caucasians and rarely found in Chinese populations,
was identified only in 2 patients. The four most preva-
lent mutations: c.235delC, c.299delAT, c.176del16, and
c.35delG, account for 23.70% (156/658) of all mutant
GJB2 alleles identified in Jiangsu Province. However, no
mutations were found in GJB2 basal promoter region
and exon 1 or splice sites, which suggested extremely
low detection rate of GJB2 basal promoter region and
exon 1 or splice sites mutation in this area.
Table 4 Mitochondrial 12S rRNA variants identified in this study
















663 A > G homoplasmy 4 0.61 3 0.65 17/22(77.3% ) 16 1.0 Yes 86 3.2
681 T > C homoplasmy 9 1.37 6 1.30 18/22(81.8% ) 30 1.8 Yes 11 0.4
709 G > A homoplasmy 143 21.73 109 23.59 14/22(63.6% ) 330 20.1 Yes 444 16.4
735 A > G homoplasmy 4 0.61 2 0.43 16/22(72.7% ) 10 0.6 Yes 3 0.1
750 A > G homoplasmy 656 99.70 460 99.57 22/22(100% ) 1638 99.8 Yes 2682 96.7
752 C > T homoplasmy 16 2.43 15 3.25 22/22(100% ) 51 3.1 Yes 20 0.7
789 T > C homoplasmy 1 0.15 0 0.00 20/22(90.9% ) 2 0.1 Yes 1 0.0
827 A > G homoplasmy 24 3.65 13 2.81 20/22(90.9% ) 54 3.3 Yes 54 2.0
961 insC homoplasmy 15 2.28 1 0.22 20/22(90.9% ) 25 1.5 Yes 37 1.4
961 delT + insC both 2 0.30 0 0.00 20/22(90.9% ) 1 0.1 Yes no data no data
961 T > C homoplasmy 1 0.15 1 0.22 20/22(90.9% ) 3 0.2 Yes 37 1.4
979C > T homoplasmy 1 0.15 0 0.00 6/22(27.3% ) 0 0.0 Yes 1 0.0
1005 T > C both 29 4.41 22 4.76 9/22(40.9% ) 72 4.4 Yes 7 0.3
1009 C > T homoplasmy 4 0.61 3 0.65 3/22(13.6% ) 10 0.6 Yes 2 0.1
1040 T > C homoplasmy 1 0.15 0 0.00 8/22(36.4% ) 0 0.0 Yes 2 0.1
1041 A > G homoplasmy 6 0.91 1 0.22 7/22(31.8% ) 11 0.7 Yes 14 0.5
1048 C > T homoplasmy 17 2.58 11 2.38 13/22(59.1% ) 48 2.8 Yes 51 1.9
1095 T > C homoplasmy 6 0.91 1 0.22 22/22(100% ) 10 0.6 Yes 5 0.2
1107 T > C homoplasmy 46 6.99 29 6.28 18/22(81.8% ) 103 6.3 Yes 34 1.3
1119 T > C homoplasmy 23 3.50 19 4.11 13/22(59.1% ) 53 3.2 Yes 26 1.0
1187 T > C homoplasmy 3 0.46 1 0.22 11/22(50% ) 0 0.0 Yes 1 0.0
1222A > G homoplasmy 1 0.15 0 0.00 22/22(100% ) 0 0.0 None 0 0.0
1282G > A homoplasmy 2 0.30 0 0.00 13/22(59.1% ) 0 0.0 Yes 2 0.1
1382A > C homoplasmy 17 2.58 11 2.38 17/22(77.3% ) 43 2.6 Yes 65 2.4
1415G > A homoplasmy 1 0.15 0 0.00 8/22(36.4% ) 1 0.1 Yes 1 0.0
1438A > G homoplasmy 658 100.00 461 99.78 22/22(100% ) 1640 99.9 Yes 2620 96.9
1494C > T homoplasmy 4 0.61 0 0.00 18/22(81.8% ) 3 0.2 Yes 1 0.0
1520 T > C homoplasmy 3 0.46 0 0.00 6/22(27.3% ) 6 0.4 Yes 3 0.1
1555A > G homoplasmy 39 5.93 0 0.00 20/22(90.9% ) 65 4.0 Yes 12 0.4
1598G > A homoplasmy 14 2.13 10 2.16 22/22(100% ) 49 3.0 Yes 67 2.5
aThe conservation index (CI) was based on the results of the multiple alignment by ClustalW. See Additional file 1: Table S1 for information on the species used to calculate the sequence conservation; bData from the

















Figure 1 12S rRNA secondary structures predicted by RNAdraw. (A) wild-type 12S rRNA; (B) 12S rRNA with the m.1222A>G variant. To the
right, which come from the corresponding panels, is shown an enlargement of the region of predicted secondary structures surrounding
nucleotide positions 1222 (bold arrows with red circles).
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NSHL of Jiangsu Province, GJB2 mutations were detected
in 14.29% (94/658) of patients with biallelic mutation, and
10.64% (70/658) of patients with monoallelic mutation.
The reason for the failure to detect a second mutant
allele in the 70 cases in the present study claims further
clarification.
One novel nucleotide alteration c.257C > G (T86R) in
coding region of GJB2 gene were identified in two deaf
siblings compound heterozygotes carrying c.605ins46
pathogenic mutation in the exon 2 of GJB2, this change
has not been reported in Connexins and Deafness muta-
tions database at http://davinci.crg.es/deafness/. The het-
erozygotes were detected from their hearing parents, thefather carried c.257C > G (T86R) mutation, while the
mother with c.605ins46 mutation, the opposite alleles of
the parents were both wild-type.
Although the majority of cases with NSHL are caused by
nuclear gene mutations, it has become clear that mtDNA
mutations can also cause deafness. In familial cases of oto-
toxicity, aminoglycoside hypersensitivity is often maternally
transmitted, suggesting that the mutation in mtDNA is the
molecular basis for this susceptibility. In the human
mtDNA genome, m.1555A >G is the most common muta-
tion in the gene. The 12S rRNA gene was proposed to be
the primary targeting site for aminoglycosides. The identi-
fied nonsyndromic deafness-causing mtDNA mutations
include m.1555A >G, m.1494C > T, m.1095 T > C and
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Currently, it is estimated that these mutations are present
in about 3.10% of patients with NSHL, but it is expected
that this number will increase as genetic testing be-
comes more readily available. In this study, 658 patients
and all controls were screened for mtDNA 12S rRNA
gene by PCR and DNA direct sequencing. We detected
30 variants in 12S rRNA gene. Among these, 39 patients
carried the mtDNA 12S rRNA m.1555A > G mutation
(5.93% ), which coincided with the previous report [15].
Four patients carried m.1494C > T mutation, 6 patients
carried m.1095 T >C mutation, and 18 patients possess
mutations at 961 position. A novel sequence variant,
m.1222A >G in the 12S rRNA gene, was identified in one
patient with profound hearing loss. Comparison of the
variant frequencies in controls, assessment of nucleotide
conservation among mammalian species, and structural
analysis of the transcript were used to analyze the
m.1222A >G mutation associated with hearing loss. To
our knowledge, the homoplasmic m.1222A >G variant in
12S rRNA gene has not been reported to date. Conserva-
tion of the nucleotide among 22 primates and alteration
of the predicted secondary structure of the 12S rRNA
transcript suggest that the m.1222A >G variant might
affect auditory function by changing the function of the
12S rRNA.
Similar to that of the GJB2 gene mutations, the associ-
ation between mtDNA mutations and hearing loss
has also a special ethnic and regional difference. In the
NSHL cases of Jiangsu population, the incidence of the
mtDNA mutation including m.1555A >G, m.1494C > T,
m.1095 T > C and mutations at position 961 in the 12S
rRNA gene appears to coincide with other populations as
previous reports [15].
In summary, the results of our study indicate that the
mutation spectrum and prevalence of GJB2 and mtDNA
12S rRNA genes in Jiangsu patients with hearing loss is
similar to other areas of China. There are in total
31.46% of patients with NSHL carry deafness-causing
mutations in GJB2 or mtDNA 12S rRNA gene. Mutation
in GJB2 gene was the most common factor, mtDNA 12S
rRNA also play an important part in the pathogenesis of
hearing loss in Jiangsu Province areas. These results in-
dicate the necessity of genetic screening for mutations of
these genes in Jiangsu patients with NSHL.Additional file
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